ABIONYX Pharma SA (EPA:ABNX)

ABIONYX Pharma Statistics

Total Valuation

ABIONYX Pharma has a market cap or net worth of EUR 115.18 million. The enterprise value is 115.93 million.

Market Cap	115.18M
Enterprise Value	115.93M

Important Dates

The last earnings date was Thursday, March 12, 2026.

Earnings Date	Mar 12, 2026
Ex-Dividend Date	n/a

Share Statistics

ABIONYX Pharma has 35.28 million shares outstanding.

Current Share Class	35.28M
Shares Outstanding	35.28M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	32.06%
Owned by Institutions (%)	4.30%
Float	21.18M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	28.09
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-21.08
EV / Sales	28.27
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-27.50

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	-176.17%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	8.61%
Revenue Per Employee	80,392
Profits Per Employee	-107,843
Employee Count	51
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +165.88% in the last 52 weeks. The beta is 0.79, so ABIONYX Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.79
52-Week Price Change	+165.88%
50-Day Moving Average	3.59
200-Day Moving Average	3.03
Relative Strength Index (RSI)	42.16
Average Volume (20 Days)	125,775

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABIONYX Pharma had revenue of EUR 4.10 million and -5.50 million in losses.

Revenue	4.10M
Gross Profit	600,000
Operating Income	-5.50M
Pretax Income	-5.50M
Net Income	-5.50M
EBITDA	-5.38M
EBIT	-5.50M
Earnings Per Share (EPS)	n/a

Balance Sheet

Cash & Cash Equivalents	n/a
Total Debt	n/a
Net Cash	n/a
Net Cash Per Share	n/a
Equity (Book Value)	n/a
Book Value Per Share	n/a
Working Capital	n/a

Cash Flow

Operating Cash Flow	-2.90M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 14.63%, with operating and profit margins of -134.15% and -134.15%.

Gross Margin	14.63%
Operating Margin	-134.15%
Pretax Margin	-134.15%
Profit Margin	-134.15%
EBITDA Margin	-131.10%
EBIT Margin	-134.15%
FCF Margin	n/a

Dividends & Yields

ABIONYX Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-4.78%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1